Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07667621 · ClinicalTrials.gov registry record · Phase 1
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
A Phase 1 study, sponsored by University of South Florida.
- Not yet
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT07667621 is a Phase 1 study that has not yet begun recruiting, run by University of South Florida. The registered enrollment target is 100 participants.
The verdict
NCT07667621, a Phase 1 study, has not yet begun recruiting, sponsored by University of South Florida.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.
Interventions
- DRUG Rimegepant
- DRUG Zavegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07667621
The ClinicalTrials.gov registry entry for NCT07667621 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimegepant is the first listed.
NCT07667621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07667621 about?
NCT07667621 is a clinical study titled "A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department". Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocate...
What is the current status of trial NCT07667621?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2026-07. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07667621?
The interventions under investigation include: Rimegepant (DRUG), Zavegepant (DRUG).
Who is sponsoring clinical trial NCT07667621?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.